Biocartis and City of Hope announced a partnership to develop a rapid, sample-to-answer blood test for early pancreatic cancer detection, using Biocartis’ Idylla technology platform. Financial terms were not disclosed, and the partners said the test is for investigational use and not for diagnostic purposes at this stage. City of Hope will contribute a microRNA-based liquid biopsy gene signature validated across international patient cohorts, and both companies said the platform aims to detect risk markers that current noninvasive FDA-approved tests miss. Biocartis will then apply its Idylla workflow to target earlier-stage disease. The partners positioned the work against a major unmet clinical need, emphasizing that early detection can substantially improve the chance of cure compared with later-stage diagnosis when treatment options narrow. Biocartis also cited its recent FDA premarket approval for an Idylla companion diagnostic in colon cancer and additional gene signature assay collaborations. If successful, the program could add a new blood-based early detection option in pancreatic cancer and strengthen Biocartis’ footprint in translational diagnostics beyond companion diagnostics.